MedTrace Logo

An International Pulmonary Embolism Registry Using EKOS

NCT03426124 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1480

Last updated 2023-02-22

Study results available
· View outcomes & findings →

Summary

This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism. The registry will include individuals who have already received the APT treatment and those that will undergo APT treatment.

Conditions

  • Pulmonary Embolism and Thrombosis

Interventions

DEVICE

EkoSonic Endovascular System with thrombolytic

The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.

Sponsors & Collaborators

  • BTG International Inc.

    collaborator OTHER

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Keith Sterling, MD · Inova Alexandria Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2020-06-30
Completion
2020-09-30
FDA Device
Yes

Countries

  • United States
  • Austria
  • France
  • Germany
  • Netherlands
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426124 on ClinicalTrials.gov